Human granzyme B regulatory B cells prevent effector CD4+CD25- T cell proliferation through a mechanism dependent from lymphotoxin alpha.
GZMB
LTA
regulation
regulatory B cell
single cell RNAseq
tolerance
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
03
2023
accepted:
05
07
2023
medline:
18
8
2023
pubmed:
17
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
Human Granzyme B (GZMB) regulatory B cells (Bregs) have suppressive properties on CD4+ effector T cells by a mechanism partially dependent on GZMB. Moreover, these cells may be easily induced in vitro making them interesting for cell therapy. We characterized this population of in vitro induced GZMB+Bregs using single cell transcriptomics. To investigate their regulatory properties, Bregs or total B cells were also co-cultured with T cells and scRNAseq was used to identify receptor ligand interactions and to reveal gene expression changes in the T cells. We find that Bregs exhibit a unique set of 149 genes differentially expressed and which are implicated in proliferation, apoptosis, metabolism, and altered antigen presentation capacity consistent with their differentiated B cells profile. Notably, Bregs induced a strong inhibition of T cell genes associated to proliferation, activation, inflammation and apoptosis compared to total B cells. We identified and validated 5 receptor/ligand interactions between Bregs and T cells. Functional analysis using specific inhibitors was used to test their suppressive properties and we identified Lymphotoxin alpha (LTA) as a new and potent Breg ligand implicated in Breg suppressive properties. We report for the first time for a role of LTA in GZMB+Bregs as an enhancer of GZMB expression, and involved in the suppressive properties of GZMB+Bregs in human. The exact mechanism of LTA/GZMB function in this specific subset of Bregs remains to be determined.
Identifiants
pubmed: 37588598
doi: 10.3389/fimmu.2023.1183714
pmc: PMC10425555
doi:
Substances chimiques
Lymphotoxin-alpha
0
Granzymes
EC 3.4.21.-
Ligands
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1183714Informations de copyright
Copyright © 2023 Sailliet, Mai, Dupuy, Tilly, Fourgeux, Braud, Giral, Robert, Degauque, Danger, Poschmann and Brouard.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mol Immunol. 2020 Sep;125:140-150
pubmed: 32682148
Nat Methods. 2020 Feb;17(2):159-162
pubmed: 31819264
Med Sci Monit. 2006 Jul;12(7):RA121-4
pubmed: 16810143
Nat Rev Immunol. 2015 Mar;15(3):160-71
pubmed: 25698678
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
J Am Soc Nephrol. 2015 Oct;26(10):2588-98
pubmed: 25644114
Bioinformatics. 2002 Aug;18(8):1135-6
pubmed: 12176838
Am J Physiol Cell Physiol. 2004 Mar;286(3):C547-55
pubmed: 14761884
Eur J Immunol. 2001 Apr;31(4):1278-87
pubmed: 11298355
Ann Rheum Dis. 1999 Nov;58 Suppl 1:I121-8
pubmed: 10577988
Eur J Immunol. 2010 Jul;40(7):2060-9
pubmed: 20394077
Nat Immunol. 2002 Oct;3(10):944-50
pubmed: 12244307
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9394-9
pubmed: 26170288
Database (Oxford). 2017 Jan 1;2017:
pubmed: 28605766
J Immunol. 2010 Dec 1;185(11):6413-9
pubmed: 21084670
Cell Rep. 2020 Jan 28;30(4):1052-1062.e5
pubmed: 31995749
Vascul Pharmacol. 2018 Dec;111:54-61
pubmed: 30243560
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Autoimmun Rev. 2012 Jul;11(9):670-7
pubmed: 22155204
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Cancers (Basel). 2021 Mar 12;13(6):
pubmed: 33809259
Eur J Immunol. 2018 Sep;48(9):1506-1521
pubmed: 30004580
Arthritis Res Ther. 2014 Oct 30;16(5):467
pubmed: 25359150
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
J Immunol. 2009 Mar 15;182(6):3492-3502
pubmed: 19265127
Cytokine. 2015 Aug;74(2):318-26
pubmed: 25742773
Am J Transplant. 2014 Jan;14(1):144-55
pubmed: 24354874
Ann Neurol. 2010 Apr;67(4):452-61
pubmed: 20437580
Cell Rep. 2022 Apr 19;39(3):110728
pubmed: 35443184
Arthritis Res Ther. 2011 Jul 26;13(4):232
pubmed: 21861866
J Immunol. 2020 Nov 1;205(9):2391-2401
pubmed: 32948686
Blood. 2011 Jan 13;117(2):530-41
pubmed: 20962324
Eur J Immunol. 2014 Jun;44(6):1728-36
pubmed: 24700192
Allergy. 2014 Nov;69(11):1454-63
pubmed: 25060230
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Methods Mol Biol. 2021;2270:203-216
pubmed: 33479900
J Exp Med. 1993 Mar 1;177(3):763-74
pubmed: 8382256
J Immunol. 2009 Aug 1;183(3):1838-45
pubmed: 19592644
J Immunol. 2002 Jul 1;169(1):424-33
pubmed: 12077273
Cancer Res. 2013 Apr 15;73(8):2468-79
pubmed: 23384943
J Exp Med. 2003 Feb 17;197(4):489-501
pubmed: 12591906
Front Immunol. 2020 Feb 19;11:255
pubmed: 32140157
Arch Immunol Ther Exp (Warsz). 2008 Mar-Apr;56(2):77-83
pubmed: 18373241
Am J Transplant. 2016 Dec;16(12):3430-3442
pubmed: 27273606
Curr Opin Organ Transplant. 2015 Aug;20(4):369-75
pubmed: 26107970
Eur J Immunol. 2020 Nov;50(11):1757-1769
pubmed: 32529638
J Immunol. 2019 Oct 15;203(8):2110-2120
pubmed: 31511354
Int Immunol. 2001 Feb;13(2):135-47
pubmed: 11157847
J Immunol. 2012 Apr 15;188(8):3961-71
pubmed: 22412197
JCI Insight. 2022 Sep 8;7(17):
pubmed: 35943811
Genome Biol. 2018 Dec 19;19(1):224
pubmed: 30567574
J Immunol. 2014 Sep 1;193(5):2258-66
pubmed: 25080484
Genome Biol. 2015 Dec 10;16:278
pubmed: 26653891
Eur J Immunol. 1996 Dec;26(12):3055-60
pubmed: 8977304
Blood. 2006 Oct 15;108(8):2712-9
pubmed: 16809616
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Cytokine Growth Factor Rev. 2011 Oct-Dec;22(5-6):311-9
pubmed: 21962830
Front Immunol. 2016 Dec 19;7:618
pubmed: 28066428
J Allergy Clin Immunol. 2013 Apr;131(4):1204-12
pubmed: 23453135
J Virol. 2002 Apr;76(8):3943-51
pubmed: 11907234
J Immunol. 2015 Apr 15;194(8):3768-77
pubmed: 25780036